leadf
logo-loader
viewValiRx PLC

ValiRx PLC making 'striking and important' progress on lead cancer compounds

Oliver de Giorgio-Miller, chairman of ValiRx Plc's (LON:VAL), tells Proactive Investors that their two lead cancer compounds are at stages in their development that they offer potential investors an investable proposition and an attractive offering to joint venture partners.

They’ve been given the green light to now expand the scope of the study around VAL201 – escalating the dosage with patients currently being recruited.

Quick facts: ValiRx PLC

Price: 20.5 GBX

AIM:VAL
Market: AIM
Market Cap: £13.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

K2fly welcomes new five-year SaaS deal with Coeur Mining

K2fly Ltd's (ASX:K2F) Nic Pollock caught up with Proactive's Andrew Scott following the news they've signed a five-year resource inventory management software as a service contract with New York Stock Exchange-listed precious metals mining company Coeur Mining Inc (NYSE:CDE) (FRA:CDM1). This...

7 hours, 5 minutes ago

2 min read